Lansoprazole: Pharmacokinetics, pharmacodynamics and clinical uses

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 10, 2001, Pages 1663-1670

  Gremse, D A ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Gastroesophageal reflux; Lansoprazole; Peptic ulcer; Proton pump inhibitor

Indexed keywords

AMOXICILLIN; BENZIMIDAZOLE DERIVATIVE; CLARITHROMYCIN; DIAZEPAM; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; MEMBRANE ENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PREDNISOLONE; PROPRANOLOL; PROTON PUMP INHIBITOR; RABEPRAZOLE; STOMACH SECRETION INHIBITOR; WARFARIN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; DUODENUM ULCER; ENZYME INHIBITION; EPIGASTRIC PAIN; ERADICATION THERAPY; GASTROINTESTINAL DISEASE; HEADACHE; HELICOBACTER PYLORI; HUMAN; HYPERGASTRINEMIA; INSOMNIA; PEPTIC ULCER; PHARYNGITIS; REFLUX ESOPHAGITIS; SKIN DISEASE; STOMACH ACID SECRETION; STOMACH PARIETAL CELL; STOMACH ULCER; SYMPTOM; TOXIC HEPATITIS; TREATMENT OUTCOME; ULCER HEALING; VERTIGO; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANIMALS; ANTI-ULCER AGENTS; ENZYME INHIBITORS; ESOPHAGITIS, PEPTIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; OMEPRAZOLE; PEPTIC ULCER; PROTON PUMPS;

EID: 0034762848     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.10.1663     Document Type: Article

References (66)

1. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota
2. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
3. Economic considerations in the treatment of gastroesophageal reflux disease: A review
4. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders
5. Agents for control of gastric acidity and treatment of peptic ulcers
6. The critical cysteine in the gastric H, K ATPase for inhibition of acid secretion by proton pump inhibitors
7. Prevacid® (lansoprazole) delayed-release capsules
8. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers
9. The effects of lansoprazole, 30 or 60 mg daily on intragastric pH and on endocrine function in healthy volunteers
10. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole
11. Pharmacokinetics/Pharmacodynamics of lansoprazole in pediatric patients with symptomatic gastroesophageal reflux disease
12. Pharmacokinetics of lansoprazole in adolescent patients with gastroesophageal reflux disease
13. Clinical study of AG-1749 (lansoprazole): Effects on serum gastrin levels and gastric mucosal ECL density, etc
14. Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment
15. Thirteen week oral toxicity study of lansoprazole (AG-1749) in rats
16. Omeprazole: An updated review of its pharmacology and therapeutic use in acid-related disorders
17. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia
18. Lansoprazole: A comprehensive review
19. Inhibition by lansoprazole of adrenocortical response to ACTH: Clinical studies and experiments on bovine adrenal cortex in vitro
20. The effect of food and antacids on lansoprazole absorption and disposition
21. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis
22. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK lansoprazole clinical research group
23. 2-receptor antagonist therapy
24. +-ATPase inhibitor: A controlled, double-blind study
25. Is there any acid peptic disease that is refractory to proton pump inhibitors?
26. 2-receptor antagonist therapy: Lansoprazole a new proton pump inhibitor
27. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis
28. Rapid symptom relief in reflux oesophagitis: A comparison of lansoprazole and omeprazole
29. Speed of heartburn relief: Lansoprazole versus omeprazole
30. Changing clinical perspectives toward gastroesophageal reflux
31. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole
32. Lansoprazole in the treatment of gastrooesophageal reflux disease in childhood
33. Efficacy of lansoprazole in the treatment of GERD in children
34. A study of clinical usefulness of lansoprazole (AG-1749) in treating gastric ulcer: A comparison with famotidine by multiclinic, double-blind technique
35. Rapid healing of gastric ulcers with lansoprazole
36. Efficacy and safety of lansoprazole in the treatment of gastric ulcer: A multicentre study
37. The proton pump inhibitors: Similarities and differences
38. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine
39. Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: A randomized, multicenter, double-masked trial
40. Lansoprazole versus omeprazole in active duodenal ulcer
41. Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer Gastroenterol
42. Lansoprazole versus omeprazole in duodenal ulcer healing
43. 2-receptor antagonists
44. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended highdose ranitidine treatment
45. Therapy with omeprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment
46. Superiority of lansoprazole vs. ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: Results of a double-blind, randomized, multicenter study
47. Helicobacter pylori in peptic ulcer disease
48. European concepts in the management of Helicobacter pylori infection: The Maastricht consensus report
49. Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers
50. Helicobacter pylori urease inhibition by rabeprazole, a proton-pump inhibitor
51. Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton-pump inhibitors
52. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori
53. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: A randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens
54. Triple therapy for with ranitidine or lansoprazole in the treatment of Helicobacter pylori associated duodenal ulcer
55. Safety of lansoprazole
56. Zollinger-Ellison syndrome: Improved treatment options for this complex disorder
57. Review article: Comparison of the pharmacokinetics, acid suppression, and efficacy of proton pump inhibitors
58. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome
59. A reappraisal of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders
60. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders
61. The effects of oral doses of lansoprazole and omeprazole on gastric pH
62. Personal review: Alarmism or legitimate concerns about long-term suppression of gastric acid secretion?
63. Personal review: Is profound acid inhibition safe?
64. Long-term acid control and proton pump inhibitors: Interactions and safety issues in perspective
65. Effect of lansoprazole and omeprazole on the metabolism of theophylline and antipyrine in man
66. Effects on 24-hour intragastric pH: A comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously